Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report released on Monday morning,Benzinga reports. D. Boral Capital currently has a $32.00 target price on the stock.

A number of other brokerages have also recently issued reports on CMPX. Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 1st. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 1st. Jefferies Financial Group raised their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Finally, Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target for the company. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $13.38.

Compass Therapeutics Stock Up 1.1 %

CMPX stock opened at $1.86 on Monday. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08. The company has a market cap of $257.21 million, a P/E ratio of -5.03 and a beta of 1.40. The business’s fifty day moving average is $2.15 and its 200-day moving average is $2.10.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Research analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Compass Therapeutics news, insider Jonathan Anderman bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This trade represents a 2,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Compass Therapeutics by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company’s stock valued at $463,000 after buying an additional 5,590 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in Compass Therapeutics in the first quarter valued at $57,000. SG Americas Securities LLC lifted its stake in Compass Therapeutics by 138.2% in the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company’s stock valued at $1,787,000 after acquiring an additional 545,767 shares during the last quarter. Simplicity Wealth LLC bought a new position in shares of Compass Therapeutics in the 1st quarter valued at about $88,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Compass Therapeutics during the 4th quarter worth about $35,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.